| Banner Home Care | |
| 575 East River Road, Suite 102, Tucson, Arizona 85704 | |
| (520) 888-1311 | |
| Name | Banner Home Care |
|---|---|
| Location | 575 East River Road, Suite 102, Tucson, Arizona |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Home Health Aide |
| Medicare ID | 37282 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 85614, 85629, 85641, 85653, 85658, 85701, 85704, 85705, 85706, 85710, 85711, 85712, 85713, 85714, 85715, 85716, 85718, 85719, 85730, 85735, 85736, 85737, 85741, 85742, 85743, 85745, 85746, 85747, 85748, 85749, 85750, 85755, 85756, 85757 |
| NPI Number | 1013452721 |
| Organization Name | BANNER HOME CARE-ARIZONA |
| Address | 575 E River Rd Ste 213, Tucson, AZ 85704 |
| Phone Number | 520-888-1311 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| NPI Number | 1609103191 |
| Organization Name | SUNLIFE HOME HEALTH, LLC |
| Doing Business As | SUNLIFE HOME HEALTH |
| Address | 627 N 6th Ave, Tucson, AZ 85705 |
| Phone Number | 520-888-1311 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| NPI Number | 1659523736 |
| Organization Name | SLHC, INC |
| Doing Business As | SUNLIFE HOME CARE |
| Address | 4500 E Grant Rd Ste C, Tucson, AZ 85712 |
| Phone Number | 520-888-1311 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| NPI Number | 1801956966 |
| Organization Name | SUNLIFE HOME CARE SERVICES, INC. |
| Address | 4525 E Skyline Dr, Suite 105, Tucson, AZ 85718 |
| Phone Number | 520-888-1311 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| Quality Rating: |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 96.8 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 97.5 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.4 | 99.6 |
| How often the home health team checked patients for depression | 98.4 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 69.4 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 70 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 90.5 | 96.4 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 74.7 | 79.6 |
| How often patients got better at getting in and out of bed | 81.1 | 81.1 |
| How often patients got better at bathing | 79.9 | 82.3 |
| How often patients’ breathing improved | 85.1 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 84 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 74.6 | 75 |
| How often home health patients had to be admitted to the hospital | 11.9 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.1 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 96.4 | 94 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
The patient survey data of Banner Home Care is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 85 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 83 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 81 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 83 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 74 | 78 |
News Archive
Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.
A research group led by Tetsushi Taguchi, a MANA Scientist at the Biomaterials Unit, International Center for Materials Nanoarchitectonics (MANA), NIMS, has developed tissue adhesive porous films that promote angiogenesis (formation of new blood vessels) without using growth factors.
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
MIT engineers have designed tiny robots that can help drug-delivery nanoparticles push their way out of the bloodstream and into a tumor or another disease site.
› Verified 5 days ago
Interim Healthcare Location: 5055 East Broadway, Suite D-104, Tucson, Arizona 85711 Ratings: Phone: (520) 747-1800 | |
Kindred At Home Location: 5255 East Williams Circle, Suite 6400, Tucson, Arizona 85711 Ratings: Phone: (520) 731-1333 | |
Dependable Home Health, Inc Location: 1121 North El Dorado Place, Suite 350, Tucson, Arizona 85715 Ratings: Phone: (520) 721-3822 | |
Intrepid Usa Healthcare Services Location: 1 West Wetmore Road, Suite 203, Tucson, Arizona 85705 Ratings: Phone: (529) 742-0272 | |
Nursecore Of Tucson Location: 2980 North Campbell, Suite 160, Tucson, Arizona 85719 Ratings: NA Phone: (520) 791-2300 | |
Nsi Nursing Service, Inc. Location: 3075 North Swan Road, Tucson, Arizona 85712 Ratings: NA Phone: (520) 731-1117 |